论文部分内容阅读
目的:评价3种抗消化性溃疡药(埃索美拉唑、莫沙比利与铝碳酸镁)联用对反流性食管炎患者的临床疗效。方法:选取医院2014年6月—2015年8月间收治的反流性食管炎患者100例,将其随机分为观察组和对照组,每组50例;观察组患者给予埃索美拉唑、莫沙比利与铝碳酸镁联用治疗,对照组患者给予奥美拉唑与莫沙比利联用治疗,比较两组患者治疗后的总有效率和不良反应的发生率。结果:观察组患者临床治疗后的总有效率为96.00%,明显高于对照组为72.00%(P<0.05);不良反应的发生率为2.00%低于对照组为6.00%(P>0.05)。结论:采用埃索美拉唑、莫沙比利与铝碳酸镁联用治疗反流性食管炎患者的临床疗效优于奥美拉唑与莫沙比利联用治疗。
Objective: To evaluate the clinical efficacy of three anti-peptic ulcer drugs (esomeprazole, mosapride and magnesium aluminum carbonate) in patients with reflux esophagitis. Methods: 100 patients with reflux esophagitis admitted in our hospital from June 2014 to August 2015 were randomly divided into observation group and control group, 50 cases in each group. Patients in observation group were treated with esomeprazole , Mosapride in combination with magnesium aluminum carbonate, and patients in the control group were treated with omeprazole and mosapride. The total effective rate and the incidence of adverse reactions in both groups were compared. Results: The total effective rate of the observation group was 96.00%, significantly higher than that of the control group (72.00%, P <0.05). The incidence of adverse reactions was 2.00% lower than that of the control group (6.00%) (P> 0.05) . Conclusions: The clinical efficacy of esomeprazole, mosapride, and magnesium aluminum carbonate in the treatment of patients with reflux esophagitis is superior to the combination of omeprazole and mosapride.